A new era of complement inhibition: are we ready for the infectious risks?
- PMID: 40932500
- DOI: 10.1007/s00467-025-06958-0
A new era of complement inhibition: are we ready for the infectious risks?
Conflict of interest statement
Declarations. Conflict of interest: The authors have no competing interests to declare that are relevant to the content of this article.
References
-
- Socié G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, Mujeebuddin A, Hillmen P, Vande Walle J, Haller H (2019) Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol 185:297–310 - DOI - PubMed - PMC
-
- Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, Trimarchi H, Kollins D, Papachristofi O, Jacinto-Sanders S, Merkel T, Guerard N, Renfurm R, Hach T, Rizk DV, APPLAUSE-IgAN Investigators (2025) Alternative complement pathway inhibition with Iptacopan in IgA nephropathy. N Engl J Med 392:531–543 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources